Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.339 EUR | +3.99% | +0.61% | +1.23% |
05-08 | UBS raises Centrica to 'buy' from 'neutral | AN |
05-03 | Jefferies cuts AJ Bell; Deutsche likes ConvaTec | AN |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company's share price in relation to its net book value makes it look relatively cheap.
- This company will be of major interest to investors in search of a high dividend stock.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Commercial REITs
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.23% | 1.82B | - | ||
-4.44% | 47.57B | A- | ||
-4.35% | 21.08B | A- | ||
+0.41% | 13.65B | A- | ||
+18.74% | 11.91B | A | ||
-5.34% | 9.7B | B+ | ||
-0.32% | 8.51B | A- | ||
-14.19% | 8.34B | B- | ||
+3.40% | 7.77B | A- | ||
-16.42% | 5.68B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- HMSO Stock
- H2V2 Stock
- Ratings Hammerson plc